Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Accretion NutravedaBOM:544694 21 Interest Coverage is 12.71 as of Mar. 2026, which is 69% above its 10-year median of 7.54. GuruFocus rates BOM:544694 with a GF Score™ of 21/100. The stock has 3 warning signs investors should review. Among 687 Drug Manufacturers companies, Accretion Nutraveda ranks worse than 50.36% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Accretion Nutraveda's
Operating Income
for the
six
months ended in Mar. 2026 was ₹34.6 Mil. Accretion Nutraveda's Interest Expense for the
six
months ended in Mar. 2026 was ₹-2.7 Mil.
Accretion Nutraveda's interest coverage for the quarter that ended in Mar. 2026 was 12.71.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Accretion Nutraveda's Interest Coverage or its related term are showing as below:
BOM:544694'
s Interest Coverage Range Over the Past 10 Years
Min: 2.96 Med: 7.54 Max: 12.57
Current: 12.57
BOM:544694's Interest Coverage is ranked worse than 50.36% of 687
companies
in the Drug Manufacturers industry
Industry Median: 12.7
vs BOM:544694: 12.57
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Accretion Nutraveda Interest Coverage Related Terms
Accretion Nutraveda Interest Coverage Historical Data
* Premium members only.
The historical data trend for Accretion Nutraveda's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Accretion Nutraveda Interest Coverage Chart
Accretion Nutraveda Annual Data
Trend
Mar23
Mar24
Mar25
Mar26
Interest Coverage
2.96
5.20
9.87
12.42
Accretion Nutraveda Semi-Annual Data
Mar23
Mar24
Mar25
Sep25
Mar26
Interest Coverage
N/A
N/A
9.53
12.42
12.71
BOM:544694 vs ZTS: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Accretion Nutraveda's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Accretion Nutraveda Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Accretion Nutraveda's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Accretion Nutraveda's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accretion Nutraveda (BOM:544694) has a Interest Coverage of 12.71 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Accretion Nutraveda and its competitors. This is 69% above median its historical median of 7.54. Over the past decade, Accretion Nutraveda's Interest Coverage has ranged from 2.96 to 12.57. According to the industry distribution chart, Accretion Nutraveda ranks #346 out of 687 companies in the Drug Manufacturers industry, placing it in the top 50.4%.
Is Accretion Nutraveda's Interest Coverage too high?
Accretion Nutraveda's current Interest Coverage of 12.71 is 69% above median its 10-year median of 7.54. Over the past 10 years, this metric has ranged from a low of 2.96 to a high of 12.57. The Drug Manufacturers industry median Interest Coverage is 12.70. Accretion Nutraveda's value of 12.71 is 0.1% above this industry median. Based on the distribution chart, Accretion Nutraveda ranks #346 out of 687 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Accretion Nutraveda has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Accretion Nutraveda's Interest Coverage compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Accretion Nutraveda ranks #346 out of 687 companies for Interest Coverage. This places Accretion Nutraveda in the lower half of its industry. The industry median Interest Coverage is 12.70. Accretion Nutraveda's value of 12.71 is 0.1% above this benchmark. Historically, Accretion Nutraveda's own Interest Coverage has ranged from 2.96 to 12.57 over the past decade. While the company's 10-year median is 7.54 vs. the industry median of 12.70, Accretion Nutraveda has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.70, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Accretion Nutraveda's current Interest Coverage of 12.71 is 0.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Accretion Nutraveda and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Accretion Nutraveda's current Interest Coverage is 12.71, which is 69% above median its own 10-year median of 7.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accretion Nutraveda stock overvalued right now?
Accretion Nutraveda (BOM:544694) has a current Interest Coverage of 12.71. The current Interest Coverage is 12.71, which is 69% above median its 10-year median of 7.54 and 0.1% above the Drug Manufacturers industry median of 12.70. Accretion Nutraveda's overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Accretion Nutraveda (BOM:544694), the current Interest Coverage is 12.71 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Accretion Nutraveda Ltd is engaged in the business of the Manufacturing of Ayurvedic and Nutraceutical products across several dosage forms, including Tablets, Capsules, Oral liquids, Oral Powders, External Preparation and Oils. It is a healthcare focused Company specializing in contract manufacturing, serving domestic as well as export markets in various countries like Sri Lanka, Singapore and the USA. The company offers a diverse range of dosage forms, leveraging both Classical Ayurvedic principles and modern nutraceutical science. Its product portfolio includes Tablets, such as film-coated and chewable varieties, for applications in liver care, gynecological care, bone and joint health, and respiratory support.
21GF Score
Get the complete analysis for BOM:544694
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544694 has been successfully added to your 
